Cargando…
The global cancer genomics consortium's symposium: new era of molecular medicine and epigenetic cancer medicine - cross section of genomics and epigenetics
The Global Cancer Genomics Consortium (GCGC) colleagues continue to function together as an interactive multidisciplinary team of cancer biologists and oncologists with interests in genomics and building a bidirectional bridge between cancer clinics and laboratories while taking advantage of shared...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362479/ |
Sumario: | The Global Cancer Genomics Consortium (GCGC) colleagues continue to function together as an interactive multidisciplinary team of cancer biologists and oncologists with interests in genomics and building a bidirectional bridge between cancer clinics and laboratories while taking advantage of shared resources among its member scientists. The GCGC includes member scientists from six institutions in Lisbon, United Kingdom, Japan, India and United States, and was formed in December 2010 for a period of five years. Driven by valuable lessons learned from the previous symposiums, the fourth GCGC Symposium focused on a cross section of genomic and epigenetic cancer medicine and it's for this reason we chose the conference theme - New Era of Molecular Medicine and Epigenetic Cancer Medicine: Cross Section of Genomics and Epigenetics. This year's symposium was co-organized by the Organization for Oncology and Translational Research (OOTR) at the Shiran Hall, Kyoto University, Kyoto, Japan, from November 14 and 15, 2014. The symposium attracted around 80 participants from 14 countries, and counted with 23 invited platform speakers. Scientific sessions included eight platform sessions and one poster session, and three plenary lectures. The symposium focused on cancer stem cells and self-renewal, cancer transcriptome, tumor heterogeneity, tumor biology, breast cancer genomics, targeted therapeutics and personalized medicine. The issues of cancer stem cells and tumor heterogeneity were echoed in most of the scientific presentations. The meeting concluded with an oral presentation by the best poster awardee and closing remarks by meeting co-chairs. |
---|